The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Abstract
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors. We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.Methods In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncology Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 weeks of treatment with erlotinib or gefitinib. We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care. Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2). Investigators, patients, and the trial sponsor were masked to treatment assignment. The primary endpoint was overall survival (from date of randomisation to death), analysed on an intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT00656136.Findings Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo). Median overall survival was 10·8 months (95% CI 10·0-12·0) in the afatinib group and 12·0 months (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74). Median progression-free survival was longer in the afatinib group (3·3 months, 95% CI 2·79-4·40) than it was in the placebo group (1·1 months, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001). No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group. Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group. The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3). These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2. Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group. We recorded two possibly treatment-related deaths in the afatinib group.Interpretation Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 weeks of previous EGFR tyrosine-kinase inhibitor treatment.Funding Boehringer Ingelheim Inc.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, as monotherapy, they have failed to overcome T790M-mediated resistance in patients (28, 29), because concentrations at which these irreversible TKIs overcome T790M activity pre-clinically are not achievable in humans due to dose-limiting toxicity related to non-selective inhibition of wild-type EGFR (30).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [28]
In the citing paper
“However, we know from clinical experience that afatinib is unable to inhibit T790M in the clinic due to a lack of a therapeutic window”
In the citing paper
“For example, studies of afatinib monotherapy showed a response rate of less than 10% among patients with acquired resistance to erlotinib or gefitinib, with a progression-free survival of approximately 4 months.13,15”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [13]
In the citing paper
“However, in lung cancer patients, afatinib is only effective in EGFR TKI naive EGFR mutant cancers and has a RR of < 10% in patients with NSCLC that have developed resistance to gefitinib or erlotinib (13).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [13]
In the citing paper
“neither Afatinib [76] nor Neratinib [77] nor Dacomitinib [78] demonstrated significant activity as single agent in patients harboring the T790M mutations.”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [76]
In the citing paper
“However, for EGFR T790M mutated lung cancer, it failed to overcome EGFR T790M-mediated resistance in patients [36, 37].”
In the citing paper
“Sixty-three percent of the patients in the afatinib group and 76% in the control group received ≥ one subsequent regimen (all mutation statuses).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Response rate was 7% versus 0.5%.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“In a prespecified analysis, participants with a complete or partial response to a first-line EGFR TKI whose tumors also had known EGFR mutation test results (58 [88%] of 66), the HR for PFS was significant (0.23), but the HR for OS was not (0.90) in the afatinib arm.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Some of the second-line studies included patients who had received > two previous regimens.15,23,47,48,51,65”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“The study found no improvement in the primary end point of OS between patients randomly assigned to afatinib and those randomly assigned to placebo, although PFS was longer in the afatinib group (3.3 v 1.1 months; HR, 0.38; 95% CI, 0.31 to 0.48; P < .001).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
In the citing paper
“Among these 96 patients, PFS was 3.3 months for those who received afatinib and 1.0 month for those who received placebo (HR, 0.55; 95% CI, 0.31 to 0.85; P = .009).15”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [15]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFayers, P. M., Aaronson, N. K., Bjordal, K., Groenvold, M., Curran, D., & Bottomley, A. (2001) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 2,520
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Pirker, R., Pereira, J. R., Szczęsna, A., von Pawel, J., Krzakowski, M. J., Ramlau, R., Vynnychenko, I. O., Park, K., Yu, C.-T., Ganul, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60569-9 · Cited by 1,346
Self-citationRational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
Bergman, B., Aaronson, N. K., Ahmedzai, S. H., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 906
Robins, J. M., & Finkelstein, D. M. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00779.x · Cited by 877
Research works printed but not linked: 2
- Hirsh, 2011, Symptom and health-related quality of life benefit from afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase III study (LUX-Lung 1), Proc World Conf Lung Cancer
- Atagi, 2011, LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib, Proc World Conf Lung Cancer
Cited by
Sorted by citations
Items 201–300 of 988
Kim, E. S., Neubauer, M., Cohn, A. L., Schwartzberg, L. S., Garbo, L. E., Caton, J. R., Robert, F., Reynolds, C. H., Katz, T. L., Chittoor, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70473-x · Cited by 69
Sjin, R. T. T., Lee, K., Walter, A. O., Dubrovskiy, A., Sheets, M. P., Martin, T. S., Labenski, M., Zhu, Z., Tester, R. W., Karp, R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0966 · Cited by 68
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Dhillon, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0358-9 · Cited by 68
Akamatsu, H., Katakami, N., Okamoto, I., Kato, T., Kim, Y. H., Imamura, F., Shinkai, M., Hodge, R. A., Uchida, H., & Hida, T. (2018) · Cancer Science · doi:10.1111/cas.13623 · Cited by 66
Koller, M. T., Warncke, S., Hjermstad, M. J., Arrarás, J. I., Pompili, C., Harle, A. S. M., Johnson, C., Chie, W., Schulz, C. K. J., Zeman, F., et al. (2015) · Cancer · doi:10.1002/cncr.29682 · Cited by 66
Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
Sueoka‐Aragane, N., Katakami, N., Satouchi, M., Yokota, S., Aoe, K., Iwanaga, K., Otsuka, K., Morita, S., Kimura, S. H., Negoro, S., et al. (2015) · Cancer Science · doi:10.1111/cas.12847 · Cited by 67
LncRNA CCAT2 promotes tumorigenesis by over-expressed Pokemon in non-small cell lung cancer
Zhao, Z., Wang, J., Wang, S., Chang, H., Zhang, T., & Qu, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.122 · Cited by 66
Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 69
Sullivan, I., & Planchard, D. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816670498 · Cited by 65
Chen, Y., Wu, J., Wang, A., Qi, Z., Jiang, T., Cheng, C., Zou, F., Hu, C., Wang, W., Wu, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.035 · Cited by 67
Self-citationZhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 66
Covalent Proximity Scanning of a Distal Cysteine to Target PI3Kα
Borsari, C., Keleş, E., McPhail, J. A., Schäfer, A., Sriramaratnam, R., Goch, W., Schaefer, T., Pascale, M. D., Bal, W., Gstaiger, M., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c13568 · Cited by 65
Mechanisms of resistance to EGFR targeted therapies
Hrustanovic, G., Lee, B. J., & Bivona, T. G. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23627 · Cited by 67
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
Mutational profiling of kinases in glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., Molenaar, R. J., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., Vandertop, W. P., Leenstra, S., Noorden, C. J. F. V., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-718 · Cited by 67
Ninomiya, T., Takigawa, N., Ichihara, E., Ochi, N., Murakami, T., Honda, Y., Kubo, T., Minami, D., Kudo, K., Tanimoto, M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0885 · Cited by 65
Yonesaka, K., Kudo, K., Nishida, S., Takahama, T., Iwasa, T., Yoshida, T., Tanaka, K., Takeda, M., Kaneda, H., Okamoto, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5286 · Cited by 64
Zhang, H. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s119162 · Cited by 64
Silva, A. P. S., Coelho, P. V., Anazetti, M. C., & Simioni, P. U. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1249551 · Cited by 62
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.576 · Cited by 62
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.04.005 · Cited by 67
Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 63
Steuer, C. E., Khuri, F. R., & Ramalingam, S. S. (2014) · Cancer · doi:10.1002/cncr.29139 · Cited by 62
Barnes, T. A., O'Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00113 · Cited by 61
Epidermal Growth Factor Receptor (EGFR) Signaling and Covalent EGFR Inhibition in Lung Cancer
Heuckmann, J. M., Rauh, D., & Thomas, R. K. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1825 · Cited by 61
Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
Melosky, B. L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00244 · Cited by 60
Workman, P., Al‐Lazikani, B., & Clarke, P. A. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.06.004 · Cited by 60
Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
Lee, C., Shiao, H., Wang, W.-C., & Hsieh, H. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.928283 · Cited by 60
Lu, X., Liu, S., Han, M., Yang, X., Sun, K., Wang, H., Mu, H., Du, Y., Wang, A., Ni, L., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.02.001 · Cited by 60
Manabe, T., Yasuda, H., Terai, H., Kagiwada, H., Hamamoto, J., Ebisudani, T., Kobayashi, K., Masuzawa, K., Ikemura, S., Kawada, I., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0956 · Cited by 60
Xu, L., Xu, B., Wang, J., Gao, Y., He, X., Xie, T., & Ye, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114900 · Cited by 62
Targeted therapies for advanced non-small cell lung cancer
Ai, X., Guo, X., Wang, J., Stancu, A. L., Joslin, P. M. N., Zhang, D., & Zhu, S. (2018) · Oncotarget · doi:10.18632/oncotarget.26428 · Cited by 60
Savas, P. S., Hughes, B. G. M., & Solomon, B. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.08.52 · Cited by 59
Zhao, Z., Xie, L., & Bourne, P. E. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00458 · Cited by 59
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
Maione, P., Sacco, P. C., Sgambato, A., Casaluce, F., Rossi, A., & Gridelli, C. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015595048 · Cited by 59
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly, S. O., Collins, D. C., Sundar, R., Popat, S., & Yap, T. A. (2017) · Drugs · doi:10.1007/s40265-017-0732-2 · Cited by 59
Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00190 · Cited by 57
Targeted therapy-induced diarrhea: A review of the literature
Pessi, M. A., Zilembo, N., Haspinger, E. R., Molino, L., Cosimo, S. D., Garassino, M. C., & Ripamonti, C. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.008 · Cited by 58
Clinical perspective of afatinib in non-small cell lung cancer
Chen, X., Zhu, Q., Zhu, L., Pei, D., Liu, Y., Yin, Y., Schüler, M., & Shu, Y. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.021 · Cited by 58
Davis, K. L., Goyal, R., Able, S. L., Brown, J., Li, L., & Kaye, J. A. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.11.002 · Cited by 57
Ramalingam, S. S., Crawford, J., Chang, A. Y., Manegold, C., Perez-Soler, R., Douillard, J.-Y., Thatcher, N., Barlési, F., Owonikoko, T. K., Wang, Y., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt371 · Cited by 57
Self-citationWecker, H., & Waller, C. F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_14 · Cited by 57
Geater, S. L., Xu, C., Zhou, C., Hu, C., Feng, J., Lü, S., Huang, Y., Li, W., Hou, M., Shi, J. H., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000517 · Cited by 56
Self-citationTao, L., Zhu, F., Xu, F., Chen, Z., Jiang, Y., & Chen, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.09.019 · Cited by 56
Self-citationTrial watch: Tumor-targeting monoclonal antibodies for oncological indications
Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 59
Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor
Tomassi, S., Lategahn, J., Engel, J., Keul, M., Tumbrink, H. L., Ketzer, J., Mühlenberg, T., Baumann, M., Schultz‐Fademrecht, C., Bauer, S., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01626 · Cited by 56
Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
Lategahn, J., Keul, M., Klövekorn, P., Tumbrink, H. L., Niggenaber, J., Müller, M. P., Hodson, L. E., Flaßhoff, M., Hardick, J., Grabe, T., et al. (2019) · Chemical Science · doi:10.1039/c9sc03445e · Cited by 56
Freiwald, M., Schmid, U., Fleury, A., Wind, S., Stopfer, P., & Staab, A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2403-2 · Cited by 54
Wang, X., Goldstein, D., Crowe, P. J., & Yang, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94745 · Cited by 55
Self-citationInterleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
Stanam, A., Gibson-Corley, K. N., Love-Homan, L., Ihejirika, N., & Simons, A. L. (2016) · Oncotarget · doi:10.18632/oncotarget.12590 · Cited by 54
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC
Haratake, N., Ozawa, H., Morimoto, Y., Yamashita, N., Daimon, T., Bhattacharya, A., Wang, K., Nakashoji, A., Isozaki, H., Shimokawa, M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.017 · Cited by 54
Neal, J. W., & Nguyen, K.-S. H. (2012) · Biologics · doi:10.2147/btt.s26558 · Cited by 53
Stanam, A., Love-Homan, L., Joseph, T. S., Espinosa-Cotton, M. M., & Simons, A. L. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.008 · Cited by 53
Clinical potential of gene mutations in lung cancer
Carper, M. B., & Claudio, P. P. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0074-1 · Cited by 55
Zhang, X., Maity, T. K., Kashyap, M. K., Bansal, M., Venugopalan, A. K., Singh, S., Awasthi, S., Marimuthu, A., Jacob, H. K. C., Belkina, N., et al. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m117.067439 · Cited by 50
Crystal Structures of Anti-apoptotic BFL-1 and Its Complex with a Covalent Stapled Peptide Inhibitor
Harvey, E. P., Seo, H., Guerra, R. M., Bird, G. H., Dhe‐Paganon, S., & Walensky, L. D. (2017) · Structure · doi:10.1016/j.str.2017.11.016 · Cited by 53
Tripathi, S. K., Pandey, K., Rengasamy, K. R. R., & Biswal, B. K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21700 · Cited by 54
Adverse kidney effects of epidermal growth factor receptor inhibitors
Izzedine, H., & Perazella, M. A. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw467 · Cited by 54
Wang, X., Zhang, F., Yang, X., Xue, M., Li, X., Gao, Y., & Liu, L. (2019) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15426271404407 · Cited by 51
Cheema, P. K., & Burkes, R. L. (2013) · Current Oncology · doi:10.3747/co.20.1226 · Cited by 50
Lin, Y.-C., Lin, Y.-C., Shih, J., Huang, W., Chao, S.-W., Chang, Y., & Chen, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1150 · Cited by 50
Predictive biomarkers in precision medicine and drug development against lung cancer
Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015) · 癌症：英文版 · doi:10.1186/s40880-015-0028-4 · Cited by 49
Petri, L., Egyed, A., Bajusz, D., Imre, T., Hetényi, A., Martinek, T. A., Ábrányi‐Balogh, P., & Keserű, G. M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112836 · Cited by 48
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Bian, D., Sun, L., Hu, J., Duan, L., Xia, H., Zhu, X., Sun, F., Zhang, L., Yu, H., Xiong, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40349-z · Cited by 49
Self-citationHirsh, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017753338 · Cited by 47
Self-citationKarlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Epidermal Growth Factor Receptor–Mutant Lung Cancer
Piotrowska, Z., & Sequist, L. V. D. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000147 · Cited by 45
Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders
Agustoni, F., Platania, M., Vitali, M., Zilembo, N., Haspinger, E. R., Sinno, V., Gallucci, R., de Braud, F., & Garassino, M. C. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.005 · Cited by 46
Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
Hossam, M., Lasheen, D. S., & Abouzid, K. A. M. (2016) · Archiv der Pharmazie · doi:10.1002/ardp.201600063 · Cited by 45
EGFR T790M: revealing the secrets of a gatekeeper
Ko, B., Paucar, D., & Halmos, B. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s117944 · Cited by 47
Reckamp, K. L., Frankel, P. H., Ruel, N. H., Mack, P. C., Gitlitz, B. J., Li, T., Koczywas, M., Gadgeel, S. M., Cristea, M. C., Belani, C. P., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00132 · Cited by 46
Ellis, P. M., Verma, S., Sehdev, S. R., Younus, J., & Leighl, N. B. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829f6a43 · Cited by 46
Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study
Doval, D. C., Choudhury, K. D., Talwar, V., Gupta, S., Mehta, A., Azam, S., & Batra, U. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.114970 · Cited by 46
Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?
Farhat, F. S., & Houhou, W. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013492001 · Cited by 45
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
Patel, J. N. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s62918 · Cited by 50
Morán, T., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1858 · Cited by 44
Sonousi, A. S. M., Hassan, R. A., Osman, E. O., Abdou, A. M., & Emam, S. H. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2118735 · Cited by 45
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 45
Nanjo, S., Yamada, T., Nishihara, H., Takeuchi, S., Sano, T., Nakagawa, T., Ishikawa, D., Zhao, L., Ebi, H., Yasumoto, K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084700 · Cited by 45
Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
Schnell, D., Buschke, S., Fuchs, H., Gansser, D., Goeldner, R.-G., Uttenreuther-Fischer, M., Stopfer, P., Wind, S., Petersen-Sylla, M., Halabi, A., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2484-y · Cited by 44
Structural basis of mutant-selectivity and drug-resistance related to CO-1686
Yan, X.-E., Zhu, S.-J., Liang, L., Zhao, P., Choi, H. G., & Yun, C.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.18588 · Cited by 43
Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
Chen, Y. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.01.010 · Cited by 41
Self-citationLi, X., & Zhou, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19007 · Cited by 43
Self-citationAuranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma
Hu, J., Zhang, H., Cao, M., Wang, L., Wu, S., & Fang, B. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1173 · Cited by 46
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
Suda, K., & Mitsudomi, T. (2014) · Progress in tumor research · doi:10.1159/000355902 · Cited by 43
Afatinib for the treatment of metastatic non-small cell lung cancer
Joshi, M., Rizvi, S., & Belani, C. P. (2015) · Cancer Management and Research · doi:10.2147/cmar.s51808 · Cited by 43
Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors
Reinwald, M., Boch, T., Hofmann, W., & Buchheidt, D. (2015) · Biomarker Insights · doi:10.4137/bmi.s22430 · Cited by 45
Husain, H., Scur, M. D., Murtuza, A., Bui, N. Q., Woodward, B. D., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0105 · Cited by 44
Hata, A., Katakami, N., Kaji, R., Yokoyama, T., Kaneda, T., Tamiya, M., Inoue, T., Kimura, H., Yano, Y., Tamura, D., et al. (2018) · Cancer · doi:10.1002/cncr.31678 · Cited by 42
Sacher, A. G., Janne, P. A., & Oxnard, G. R. (2014) · Cancer · doi:10.1002/cncr.28723 · Cited by 42
Dermatological Toxicity Associated with Targeted Therapies in Cancer: Optimal Management
Peuvrel, L., & Dréno, B. (2014) · American Journal of Clinical Dermatology · doi:10.1007/s40257-014-0088-2 · Cited by 41
Tan, F., Shi, Y., Wang, Y., Ding, L., Yuan, X., & Sun, Y. P. (2015) · Future Oncology · doi:10.2217/fon.14.249 · Cited by 42
Self-citationManagement of EGFR mutated nonsmall cell lung carcinoma patients
Grigoriu, B. D., Berghmans, T., & Meert, A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00156614 · Cited by 41
Venugopalan, A., Lee, M.-J., Niu, G., Medina-Echeverz, J., Tomita, Y., Lizak, M. J., Cultraro, C. M., Simpson, R. M., Chen, X., Trepel, J. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11021 · Cited by 40
Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer
Viganò, M., Milia, M. L., Grassini, M. V., Pugliese, N., Giorgio, M. D., & FAGIUOLI, S. (2023) · Cancers · doi:10.3390/cancers15061766 · Cited by 43
Márquez-Medina, D., & Popat, S. (2015) · Future Oncology · doi:10.2217/fon.15.183 · Cited by 40
The Potential of panHER Inhibition in Cancer
Wang, X., Batty, K., Crowe, P. J., Goldstein, D., & Yang, J. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00002 · Cited by 40
Self-citationCeritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non–Small-Cell Lung Cancer
Li, S., Qi, X., Huang, Y., Liu, D., Zhou, F., & Zhou, C. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.09.011 · Cited by 41
Self-citationExtending Survival of Stage IV Non-Small Cell Lung Cancer
Carnio, S., Novello, S., Mele, T., Levra, M. G., & Scagliotti, G. V. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.013 · Cited by 40
Kuan, F., Li, S., Wang, C., Lin, M., Tsai, Y., & Yang, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13815 · Cited by 40
Metadata
- Authors
- Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, E.-H., Chao, T.-Y., Shahidi, M., Cong, X. J., Lorence, R. M., & Yang, J. C.-H.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- McGill University Health Centre (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Taipei Veterans General Hospital (TW)
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Tongji University (CN)
- National Cheng Kung University Hospital (TW)
- Peking Union Medical College Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Seoul National University Hospital (KR)
- National Cancer Centre Singapore (SG)
- Taipei Medical University-Shuang Ho Hospital (TW)
- Boehringer Ingelheim (United Kingdom) (GB)
- Boehringer Ingelheim (United States) (US)
- National Taiwan University (TW)
- Corresponding author
- Yang, James Chih-Hsin
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-05
- Volume
- 13
- Issue
- 5
- Pages
- 528-538
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152905269
- Cited by
- 961
- References
- 29
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 28 · 2023: 38 · 2022: 33 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 70 · 2017: 103 · 2016: 99 · 2015: 125 · 2014: 139 · 2013: 107 · 2012: 37
- FWCI
- 105.26
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-05-01)
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, non-small cell lung cancer, lung adenocarcinoma, EGFR tyrosine kinase inhibitors, erlotinib, gefitinib, EGFR mutation, EGFR inhibitor resistance, second-line therapy, overall survival, progression-free survival, best supportive care, targeted therapy
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Afatinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Quinazolines, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
